MX2016007653A - Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer. - Google Patents
Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.Info
- Publication number
- MX2016007653A MX2016007653A MX2016007653A MX2016007653A MX2016007653A MX 2016007653 A MX2016007653 A MX 2016007653A MX 2016007653 A MX2016007653 A MX 2016007653A MX 2016007653 A MX2016007653 A MX 2016007653A MX 2016007653 A MX2016007653 A MX 2016007653A
- Authority
- MX
- Mexico
- Prior art keywords
- panitumumab
- cancer
- combinations
- treatment
- dabrafenib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Una nueva combinación que comprende un inhibidor de la B-Raf, particularmente N-{3-[5-(2-Amino-4-pirimidinil)-2-(1,1-dimetiletil )-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobencenosulfonamida o una sal farmacéuticamente aceptable del mismo, y/o el inhibidor de MEK N-{3-[3-ciclopropil-5-(2-fluoro-4-iodo-fenilamino)6,8-dimet il;-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-i l]fenil}acetamida, o una sal farmacéuticamente aceptable o solvato del mismo, y panitumumab (Vectibix); composiciones farmacéuticas que comprenden los mismos y métodos de uso de tales combinaciones y composiciones en el tratamiento de condiciones en las que la inhibición de MEK y/o B-Raf y/o EGFR es beneficiosa, por ejemplo, cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361915041P | 2013-12-12 | 2013-12-12 | |
US201462004579P | 2014-05-29 | 2014-05-29 | |
PCT/IB2014/066814 WO2015087279A1 (en) | 2013-12-12 | 2014-12-11 | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016007653A true MX2016007653A (es) | 2016-10-13 |
Family
ID=52146562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007653A MX2016007653A (es) | 2013-12-12 | 2014-12-11 | Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160367662A1 (es) |
EP (1) | EP3079698A1 (es) |
JP (1) | JP2017500307A (es) |
KR (1) | KR20160088884A (es) |
CN (1) | CN106029074A (es) |
AU (1) | AU2014362995A1 (es) |
BR (1) | BR112016011222A2 (es) |
CA (1) | CA2933311A1 (es) |
MX (1) | MX2016007653A (es) |
WO (1) | WO2015087279A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
WO2017070475A1 (en) * | 2015-10-22 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies |
MX2018009581A (es) | 2016-02-06 | 2019-05-06 | Epimab Biotherapeutics Inc | Inmunoglobulina con fabs en tandem y sus usos. |
CR20190002A (es) * | 2016-06-03 | 2019-06-10 | Zhu Alexander Cao | Combinaciones farmacéuticas |
CN106539777A (zh) * | 2016-11-25 | 2017-03-29 | 佳木斯大学 | 一种甲磺酸达拉非尼缓释片及其制备方法 |
EP3846799A1 (en) | 2018-07-24 | 2021-07-14 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Combined therapy inhibiting expression, activity and/or function of epidermal growth factor receptor and c-raf against cancer |
EP3598973A1 (en) | 2018-07-24 | 2020-01-29 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Combined therapy against cancer |
KR102192576B1 (ko) | 2019-03-21 | 2020-12-17 | 경북대학교 산학협력단 | 다브라페닙을 유효성분으로 포함하는 알레르기 질환 예방, 치료 또는 개선용 조성물 |
KR102275782B1 (ko) * | 2019-06-18 | 2021-07-09 | 주식회사 스탠다임 | 대사성 간질환의 예방 또는 치료용 조성물 |
CN115490640A (zh) * | 2021-06-17 | 2022-12-20 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
EP0947478B1 (en) | 1998-02-13 | 2005-07-13 | Central Glass Company, Limited | Water-repellent solution and method of forming water-repellent film on substrate by using the solution |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
CN101006086B (zh) | 2004-06-11 | 2010-09-29 | 日本烟草产业株式会社 | 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物 |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
SI2488033T1 (sl) * | 2009-10-16 | 2019-10-30 | Novartis Ag | Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF |
BR112015009134A2 (pt) * | 2012-10-25 | 2017-07-04 | Glaxosmithkline Llc | combinação |
-
2014
- 2014-12-11 KR KR1020167015238A patent/KR20160088884A/ko not_active Application Discontinuation
- 2014-12-11 WO PCT/IB2014/066814 patent/WO2015087279A1/en active Application Filing
- 2014-12-11 EP EP14819083.8A patent/EP3079698A1/en not_active Withdrawn
- 2014-12-11 BR BR112016011222A patent/BR112016011222A2/pt not_active Application Discontinuation
- 2014-12-11 MX MX2016007653A patent/MX2016007653A/es unknown
- 2014-12-11 JP JP2016538556A patent/JP2017500307A/ja active Pending
- 2014-12-11 AU AU2014362995A patent/AU2014362995A1/en not_active Abandoned
- 2014-12-11 CA CA2933311A patent/CA2933311A1/en not_active Abandoned
- 2014-12-11 US US15/100,795 patent/US20160367662A1/en not_active Abandoned
- 2014-12-11 CN CN201480075171.9A patent/CN106029074A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2933311A1 (en) | 2015-06-18 |
US20160367662A1 (en) | 2016-12-22 |
EP3079698A1 (en) | 2016-10-19 |
WO2015087279A1 (en) | 2015-06-18 |
KR20160088884A (ko) | 2016-07-26 |
JP2017500307A (ja) | 2017-01-05 |
CN106029074A (zh) | 2016-10-12 |
BR112016011222A2 (pt) | 2017-09-19 |
AU2014362995A1 (en) | 2016-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016007653A (es) | Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer. | |
MX2012004413A (es) | Combinacion. | |
PH12015502415A1 (en) | Combinations | |
WO2014066606A3 (en) | Combination | |
IL262964B (en) | Preparation of (s)-n-(5-((r)-2-(5,2-difluorophenyl)pyrrolidine-1-yl)pyrazolo[5,1-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide and their salts | |
MX2021014509A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
IL247721B (en) | Compositions comprising solid dispersions of (s)-n-((s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide for use in the treatment of advanced solid tumors | |
NZ610746A (en) | Methods of treatment using selective bcl-2 inhibitors | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
MX370099B (es) | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. | |
RS54651B1 (en) | JANUS KINAS INHIBITORS for the treatment of dry eye and other eye diseases | |
MX2013005020A (es) | Composiciones y metodos para el tratamiento de la mielofibrosis. | |
PH12017500724A1 (en) | Carbazole derivatives | |
MY190849A (en) | Methods of treating multiple sclerosis | |
MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
EA201270537A1 (ru) | Комбинация | |
PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
WO2013019620A3 (en) | Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody | |
WO2012036919A3 (en) | Combination of braf and vegf inhibitors | |
MX2016012050A (es) | Una composicion para el uso en el tratamiento de dolor relacionado con discos intervertebrales. | |
EA201270475A1 (ru) | Комбинация | |
EA201690762A1 (ru) | {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек | |
PH12016502285A1 (en) | Pharmaceutical composition for oral administration | |
EP3177625A4 (en) | Amorphous form of 4-((4(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |